Abstract P3-08-54: Pattern of hepatic metastasis as a prognostic index in breast cancer liver metastasis

Alternatively-activated pathways have been observed in biological experiments in cancer studies, but the concept had not been fully explored in computational cancer system biology. Therefore, an alternatively-activated pathway identification method was proposed and applied to primary breast cancer and breast cancer liver metastasis research using microarray data. Interestingly, the results show that cytokine-cytokine receptor interaction and calcium signaling were significantly enriched under both conditions. TGF beta signaling was found to be the hub in network topology analysis. In total, three types of alternatively-activated pathways were recognized. In the cytokine-cytokine receptor interaction pathway, four active alteration patterns in gene pairs were noticed. Thirteen cytokine-cytokine receptor pairs with inverse activity changes of both genes were verified by the literature. The second type was that some sub-pathways were active under only one condition. For the third type, nodes were significantly active in both conditions, but with different active genes. In the calcium signaling and TGF beta signaling pathways, node E2F5 and E2F4 were significantly active in primary breast cancer and metastasis, respectively. Overall, our study demonstrated the first time using microarray data to identify alternatively-activated pathways in breast cancer liver metastasis. The results showed that the proposed method was valid and effective, which could be helpful for future research for understanding the mechanism of breast cancer metastasis.

Download Full-text

Microwave ablation for breast cancer liver metastasis

HPB ◽

10.1016/j.hpb.2019.10.1187 ◽

2019 ◽

Vol 21 ◽

pp. S943

Author(s):

E. Gringeri ◽

R. Boetto ◽

S.E. Pierobon ◽

F.E. D'Amico ◽

D. Bassi ◽

...

Keyword(s):

Breast Cancer ◽

Liver Metastasis ◽

Microwave Ablation ◽

Breast Cancer Liver Metastasis

Download Full-text

Results of hepatic resection following breast cancer liver metastasis

HPB ◽

10.1016/j.hpb.2019.10.374 ◽

2019 ◽

Vol 21 ◽

pp. S639

Author(s):

K. Kobryń ◽

E. Kobryń ◽

K. Kobryń ◽

M. Nowosad ◽

W. Patkowski ◽

...

Keyword(s):

Breast Cancer ◽

Liver Metastasis ◽

Hepatic Resection ◽

Breast Cancer Liver Metastasis

Download Full-text

Radiofrequency Ablation (RFA) as A Cytoreductive Strategy for Hepatic Metastasis from Breast Cancer

Annals of The Royal College of Surgeons of England ◽

10.1308/003588406x149129 ◽

2006 ◽

Vol 88 (7) ◽

pp. 639-642 ◽

Cited By ~ 43

Author(s):

D Lawes ◽

A Chopada ◽

A Gillams ◽

W Lees ◽

I Taylor

Keyword(s):

Breast Cancer ◽

Radiofrequency Ablation ◽

Liver Metastasis ◽

Hepatic Metastasis ◽

Primary Breast Cancer ◽

Hepatic Disease ◽

Extrahepatic Disease ◽

Major Morbidity ◽

Disease Free

INTRODUCTION Patients with liver metastasis from breast cancer have a poor prognosis, although this may be improved by hepatectomy in a selected group with disease confined to the liver. We evaluate the effectiveness of radiofrequency ablation (RFA) as a cytoreductive strategy in the management of liver metastasis from primary breast cancer. PATIENTS AND METHODS Nineteen patients with hepatic metastasis from primary breast cancer underwent RFA of their liver lesions between April 1998 and August 2004. RESULTS The median age of the patients was 52 years (range, 32–69 years), 8 had disease confined to the liver, with 11 having stable extrahepatic disease in addition. Seven patients with disease confined to the liver at presentation are alive, as are 6 with extrahepatic disease, median follow-up after RFA was 15 months (range, 0–77 months). Survival at 30 months was 41.6%. In addition, 7 patients followed up for a median of 14 months (range, 2–29 months) remain alive and disease-free. RFA failed to control hepatic disease in 3 patients. RFA was not associated with any mortality or major morbidity. CONCLUSIONS Control of hepatic metastasis from breast cancer is possible using RFA and may lead to a survival benefit, particularly in those patients with disease confined to the liver.

Download Full-text

Liver Transplant in Patient with Breast Cancer Liver Metastasis and Hepatic Failure

Digestive and Liver Disease ◽

10.1016/j.dld.2020.12.110 ◽

2021 ◽

Vol 53 ◽

pp. S46

Author(s):

V. Giannelli ◽

R. Meniconi ◽

N. Guglielmo ◽

M. Colasanti ◽

C. D'Ambrosio ◽

...

Keyword(s):

Breast Cancer ◽

Liver Metastasis ◽

Liver Transplant ◽

Hepatic Failure ◽

Breast Cancer Liver Metastasis

Download Full-text

Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis

Annals of Surgery ◽

10.1097/sla.0000000000001371 ◽

2016 ◽

Vol 264 (1) ◽

pp. 147-154 ◽

Cited By ~ 40

Author(s):

Eran Sadot ◽

Ser Yee Lee ◽

Constantinos T. Sofocleous ◽

Stephen B. Solomon ◽

Mithat Gönen ◽

...

Keyword(s):

Breast Cancer ◽

Liver Metastasis ◽

Hepatic Resection ◽

Breast Cancer Liver Metastasis

Download Full-text

Hepatectomy, RFA, and Other Liver Directed Therapies for Treatment of Breast Cancer Liver Metastasis: A Systematic Review

Frontiers in Oncology ◽

10.3389/fonc.2021.643383 ◽

2021 ◽

Vol 11 ◽

Author(s):

Kevin Rivera ◽

Dhiresh Rohan Jeyarajah ◽

Kimberly Washington

Keyword(s):

Breast Cancer ◽

Systematic Review ◽

Liver Metastasis ◽

Hepatic Resection ◽

Cancer Metastasis ◽

Cochrane Review ◽

Hepatic Arterial Infusion ◽

Breast Cancer Metastasis ◽

Arterial Infusion ◽

Breast Cancer Liver Metastasis

BackgroundThe liver is the second most common site of breast cancer metastasis. Liver directed therapies including hepatic resection, radiofrequency ablation (RFA), transarterial chemo- and radioembolization (TACE/TARE), and hepatic arterial infusion (HAI) have been scarcely researched for breast cancer liver metastasis (BCLM). The purpose of this review is to present the known body of literature on these therapies for BCLM.MethodsA systematic review was performed with pre-specified search terms using PubMed, MEDLINE, EMBASE, and Cochrane Review resulting in 9,957 results. After review of abstracts and application of exclusion criteria, 51 studies were included in this review.ResultsHepatic resection afforded the longest median overall survival (mOS) and 5-year survival (45 mo, 41%) across 23 studies. RFA was presented in six studies with pooled mOS and 5-year survival of 38 mo and 11–33%. Disease burden and tumor size was lower amongst hepatic resection and RFA patients. TACE was presented in eight studies with pooled mOS and 1-year survival of 19.6 mo and 32–88.8%. TARE was presented in 10 studies with pooled mOS and 1-year survival of 11.5 mo and 34.5–86%. TACE and TARE populations were selected for chemo-resistant, unresectable disease. Hepatic arterial infusion was presented in five studies with pooled mOS of 11.3 months.ConclusionAlthough further studies are necessary to delineate appropriate usage of liver directed therapies in BCLM, small studies suggest hepatic resection and RFA, in well selected patients, can result in prolonged survival. Longitudinal studies with larger cohorts are warranted to further investigate the effectiveness of each modality.

Download Full-text